<div id="readability-page-1"><p>Stance Capital LLC acquired a new position in shares of  The Clorox Company (NYSE:CLX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor  acquired 12,989 shares of the company's stock, valued at approximately $1,560,000.</p><ul><li>3 Defensive Stocks to Buy as Economic Uncertainty Lingers</li></ul><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Investments LLC raised its holdings in  Clorox by 4.4% during the first quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock worth $258,000 after purchasing an additional 75 shares in the last quarter.  Hancock Whitney Corp raised its stake in shares of  Clorox by 4.3% during the 1st quarter. Hancock Whitney Corp now owns 2,064 shares of the company's stock worth $304,000 after buying an additional 86 shares in the last quarter.  Brown Lisle Cummings Inc. lifted its holdings in shares of  Clorox by 4.3% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 2,136 shares of the company's stock valued at $256,000 after buying an additional 89 shares during the period.  American National Bank &amp; Trust lifted its holdings in shares of  Clorox by 69.5% in the 2nd quarter. American National Bank &amp; Trust now owns 217 shares of the company's stock valued at $26,000 after buying an additional 89 shares during the period.  Finally, Savvy Advisors Inc. boosted its stake in shares of  Clorox by 1.4% in the second quarter. Savvy Advisors Inc. now owns 6,395 shares of the company's stock valued at $768,000 after buying an additional 91 shares in the last quarter. Hedge funds and other institutional investors own  78.53% of the company's stock. </p><h2>Clorox Stock Up 1.1%</h2><p>CLX opened at $103.98 on Friday. The firm has a market cap of $12.68 billion, a P/E ratio of 16.32, a PEG ratio of 0.52 and a beta of 0.57. The business's fifty day simple moving average is $109.89 and its 200 day simple moving average is $119.22. The Clorox Company has a 52 week low of $98.20 and a 52 week high of $166.35. The company has a quick ratio of 0.50, a current ratio of 0.76 and a debt-to-equity ratio of 18.01. </p><ul><li>3 Dividend Stocks Raising Payouts—and Backing It Up With Results</li></ul><p>Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.78 by $0.07. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The firm's quarterly revenue was down 18.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.86 EPS. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS.  As a group, equities research analysts anticipate that  The Clorox Company will post 7.15 EPS for the current fiscal year. </p><h2>Clorox Dividend Announcement</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be issued a $1.24 dividend. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 annualized dividend and a yield of 4.8%. Clorox's payout ratio is 77.86%. </p><h2>Insider Activity</h2><ul><li>Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out</li></ul><p>In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of $104.13 per share, with a total value of $416,520.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at approximately $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.63% of the stock is owned by company insiders. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have commented on the company. Citigroup reduced their target price on Clorox from $130.00 to $120.00 and set a &#34;neutral&#34; rating for the company in a report on Tuesday, November 4th. BNP Paribas Exane reduced their price objective on shares of Clorox from $110.00 to $103.00 and set an &#34;underperform&#34; rating for the company in a research note on Tuesday, November 4th. Weiss Ratings  restated a &#34;hold (c-)&#34; rating on shares of Clorox in a research report on Tuesday, October 14th. UBS Group  set a $119.00 target price on shares of Clorox and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Finally, Barclays lowered their price target on Clorox from $112.00 to $108.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 4th. One research analyst  has rated the stock with a Buy rating, thirteen have given a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Reduce&#34; and an average target price of $125.69.</p><p><b>Read Our Latest Report on CLX</b></p><h2>About Clorox</h2> (Free Report)<p>The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.</p><h2>Read More</h2><ul><li>Five stocks we like better than Clorox</li><li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>How to Use the MarketBeat Dividend Calculator</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><strong>Want to see what other hedge funds are holding CLX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Clorox Right Now?</h2><p>Before you consider Clorox, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.</p><p>While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Stance Capital LLC acquired 12,989 shares of The Clorox Company, valued at $1,560,000, in Q2. Other institutional investors also adjusted their positions. Clorox reported Q3 earnings of $0.85 per share, beating estimates, with revenue of $1.43 billion. The company announced a quarterly dividend of $1.24 per share. Analysts have mixed ratings, with Citigroup and BNP Paribas Exane lowering their target prices.</p>

Stance Capital LLC Acquires New Stake in The Clorox Company $CLX